{"id":"NCT00368069","sponsor":"UCB Pharma","briefTitle":"A Study to Look at the Efficacy and Safety of Keppra® Extended Release Formulation - XR","officialTitle":"A Double-blind, Placebo-controlled, Randomized Efficacy and Safety Study of Keppra® Extended Release Formulation - XR Once Daily as add-on Therapy in Subjects From 12 to 70 Years With Refractory Epilepsy Suffering From Partial Onset Seizures.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-08","primaryCompletion":"2007-05","completion":"2007-05","firstPosted":"2006-08-24","resultsPosted":"2009-07-28","lastUpdate":"2020-07-15"},"enrollment":158,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"Keppra® extended release formulation - XR","otherNames":["Levetiracetam XR"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Keppra® XR","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a safety and efficacy study of Keppra® extended release formulation - XR in patients with epilepsy.","primaryOutcome":{"measure":"Partial Onset Seizure (POS) Frequency Per Week - Intention-To-Treat (ITT) Population","timeFrame":"Treatment period (12 weeks)","effectByArm":[{"arm":"Keppra®","deltaMin":0.912,"sd":0.053},{"arm":"Placebo","deltaMin":1.067,"sd":0.052}],"pValues":[{"comp":"OG000 vs OG001","p":"0.038"},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":34,"countries":["Brazil","Finland","India","Mexico","Russia","South Africa","Ukraine"]},"refs":{"pmids":["19317886","19699156"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":77},"commonTop":["Headache","Influenza","Nasopharyngitis","Somnolence","Nausea"]}}